Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in Group 1 Pulmonary Hypertension
IRCT20171120037376N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of spironolactone in pulmonary arterial hypertension (PAH), sponsored by Mashhad University of Medical Sciences. Started Dec 2017; status: completed.
02
Drugs
spironolactone
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on IRCT20171120037376N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171120037376N1.